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We compared the composition and opsonic activities for
two common microbial pathogens (Staphylococcus aureus
and Streptococcus pyogenes) of various imported
intravenous (IV) (Sandoglobulin, Octagam and
Gammagard) and intramuscular (IM) (Beriglobin and
Globuman Berna) immunoglobulin (Ig) preparations with
those of the corresponding locally manufactured products,
Polygam (IV) and Intragam (IM). When tested at equivalent
concentrations (1 g/1 00 ml) the total IgG and IgG sub-
class concentrations of the various IV and IM preparations
were similar. All the test preparations (IV and IM)
possessed similar opsonic activity for S. aureus and S.
pyogenes. These findings demonstrate that, in respect of
IgG content and protective biological activity, Intragam
and Polygam, the locally manufactured IM and IV Ig
preparations, respectively, compared extremely favourably
with the corresponding imported products.
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Intramuscular (IM) and intravenous (IV) immunoglobulin (Ig)
preparations consist of IgG concentrates and are used
primarily as prophylactic agents in the substitution therapy
of inherited and acquired antibody deficiency states such as
agammaglobulinaemia and hypogammaglobulinaemia,
including IgG subclass deficiencies with and without
deficiency of IgA.'.2 IV Ig preparations, which contain Fc
region-unmodified, functionally intact IgG molecules, are
significantly more efficacious than IM preparations in
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reducing both the frequency and the severity of bacterial
infections in antibody-deficient individuals.3The clinical
application of IV Ig preparations is not, however, limited to
IgG replacement therapy of antibody deficiency states. Their
usefulness in the treatment of idiopathic thrombocytopenic
purpura and Kawasaki disease is well established,3.4 while
beneficial effects of administration of high-dose IV Ig have
been reported in several other acute and chronic auto-
immune diseases, including pure red cell aplasia, chronic
inflammatory demyelinating neuropathy,3 ophthalmopathy
associated with thyroid disease,3 auto-immune neutropenia,s
recent-onset diabetes mellitus,· systemic lupus
erythematosus,"· bullous pemphigoid,· myasthenia gravis,'o
polymyositis,",12 rheumatoid arthritis" (including patients
refractory to chemotherapy with first- and second-line
drugs)," and juvenile chronic arthritis.15.'. Encouraging results
have also been reported in other conditions which may not
have an auto-immune cause, such as spontaneous recurrent
abortion, intractable childhood epilepsy, myalgic
encephalomyelitis, severe steroid-dependent asthma and
chronic inflammatory bowel disease (reviewed by WebsterJ).
Moreover, IV Ig not onlyreduces the frequency of bacterial
infections in children with symptomatic human
immunodeficiency virus (HIV) infection17 but may also protect
against T-cell deletion.'·
Given the ever-increasing list of human diseases which
are apparently responsive to administration of IV IQ, we
investigated the Ig composition and opsonic activities of




The various IV and IM Jg preparations investigated in this
study are listed in Table I. With the exception of Octagam
(liqUid), all the IV 19 preparations were freeze-dried and
reconstituted in sterile physiological saline. In the assays of
Ig composition and opsonic activity described below the
various 19 preparations (IV and IM) were tested at an
identical final concentration of 1 g 19/100 ml. Pooled serum
from blood specimens taken from 12 young, healthy adult
human volunteers was decomplemented ($'6°C/~0 min) and
used as a reference source for the assays of 19 content and
opsonic activity described below. .
Immunoglobulin lelf~!~
Concentrations of total IgG, IgM and IgA in the various test
preparations and pooled control serum were measured
using standard laser nephelometric procedures in the
Department of Chemical Pathology, Institute for Pathology,
University of Pretoria. IgE levels were measured by radio-
immunoassay (Pharmacia, Uppsala, Sweden), while levels of
the IgG subclasses (lgG" IgG2, IgG3and IgGJ were
determined by radial immunodiffusion (The Binding Site Ltd,
Birmingham, England). All preparations were assayed at a
concentration of 1 g protein/100 ml.
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Table I. IV and IM immunoglobulin preparations




Polygam IV GIV18, GIV21 and GIV25
Beriglobin IM 017/1B 5
Globuman Berna IM 120010103
Intragam IM GH66, GL99 and GH74
Manufacturer/distributor
Baxter Healthcare, Hyland Division, Glendale, Calif., USA;
distributed by SABAX, Johannesburg
Octapharma AG, Glarus, Switzerland; not clinically available in South Africa.
Swiss Red Cross; distributed by Sandoz Products, Johannesburg
Natal Blood Transfusion Service, Durban
Hoechst AG, Frankfurt, Germany
Swiss Serum and Vaccine Institute, Berne, Switzerland;
distributed by Swisspharm, Johannesburg
Natal Blood Transfusion Service, Durban
Opsonic activity
For purposes of comparison all the test Ig preparations were
used at a fixed concentration of 1 g/100 ml IgG in these
assays. The opsonic activity of the various Ig preparations
was measured according to the extent of uptake or
iodination of bacteria by human neutrophils in vitro.
Staphylococcus aureus (ATCC25923) or Streptococcus
pyogenes (clinical isolate, obtained from the South African
Institute for Medical Research, Johannesburg) were used as
the test microbial pathogens in assays of opsonic activity.
Neutrophils were prepared from heparinised (5 U
preservative-free heparin/mI blood) venous blood taken from
healthy, adult human volunteers using standard methods.
Briefly, the blood was centrifuged on Ficoll-Hypaque
gradients, followed by sedimentation of erythrocytes in the
neutrophil/erythrocyte pellet with 3% gelatin and removal of
residual erythrocytes in the neutrophil-enriched supernatant
by treatment with 0,83% NH,CI. Neutrophils were
resuspended to 1 x 10'/ml in Hanks's balanced salt solution
(HBSS) (Highveld Biological, Johannesburg).
Uptake of opsonised S. aureus by neutrophils was
measured by a modification of the method of Peterson
et a/. '9 S. aureus micro-organisms were radiolabelled during
overnight culture in 10 ml nutrient broth containing 5 ~Ci
radiolabelled amino acids (L-amino acid mixture r'C(U)],
specific activity 55 rriCi per milliatom of carbon, Du Pont-
NEN Research Products, Boston, Mass, USA). The bacteria
were then washed and resuspended to a concentration of
2 x 10· colony-forming units (CFU)/ml. In assays of opsonic
activity neutrophils (4 x10") were co-incubated with S.
aureus at a ratio of 1 neutrophil to 50 CFU for 60 minutes
(predetermined in preliminary experiments) at 3rC in a final
volume of 1 ml HBSS containing the different Ig preparations
or pooled serum (10%). The neutrophil bacteria mixtures
were rotated on a turntable throughout the 60-minute
incubation period, after which the neutrophils and cell-
associated S. aureus were separated from non-adherent
bacteria by differential centrifugation (1 000 rpm/5 min). The
cell-associated bacteria were released by treatment of the
neutrophil pellets with 0,4 ml 1% Triton X-1 00/0,1 M NaOH
and the radioactivity was measured in a liquid scintillation
spectrometer.
S. pyogenes could not be used in this assay because of
the tendency of these micro-organisms to form aggregates,
thus complicating the separation of neutrophil-associated
and non-adherent bacteria. The opsonic activity ofthe test
preparations for S. pyogenes was therefore measured by an
alternative assay, viz. myeloperoxidase-mediated (~PO)
iodination.20 •
MPO iodination
Using this assay, reaction mixtures contained neutrophils
(4 x 106) and S. pyogenes micro-organisms at a ratio of 1:50,
0,6 ~Ci of a ' 25I-labelled solution of sodium iodide (Du Pont-
NEN), and the various Ig preparations or heat-inactivated
pooled normal serum (10%) in a final volume of 1 ml HBSS.
After 60 minutes' incubation at 37°C the reactions were
terminated by the addition of 10% trichloroacetic acid (TCA),
and after three washes with TCA the amount of cell-
associated 1251 was determined in a solid-state gamma
counter.
Expression and statistical analysis of
results
The results for each series of experiments are expressed as
mean values ± the standard error (SE).
Results
Immunoglobulin levels
These are set out in Tables 11 and Ill. Intragam, the locally
manufactured IM product, compared favourably with the
two imported IM preparations (Beriglobin and Globuman
Berna) in respect of content of total IgG and IgG subclasses
(Table 11), relative proportions of the IgG subclasses
(Table Ill), and levels of contaminating IgA, IgE and IgM. Of
the four IV preparations tested, the total IgG and IgG
subclass levels of Polygam (batches GIV 18, 21 and 25)
were comparable with those of Sandoglobulin, Octagam and
Gammagard. Levels of contaminating IgA, IgE and IgM were
minimal in all the test IV preparations.
Opsonic activity
These data are shown in Figs 1 and 2 for opsonisation of
S. aureus and S. pyogenes, respectively. All the test
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Table 11. Immunoglobulin composition of the test preparations
TotallgG IgG, IgG2 IgG3 IgG. IgA IgM IgE
Immunoglobulin source
Pooled serum 11,9 10,6 5,7 1,3 0,77 1,88 1,65 55
IV Ig preparations
Sandoglobulin 10,9 6,61 3,93 0,46 0,25 0,18 <0,04 9,1
Octagam 10,7 5,43 4,24 0,42 0,12 <0,07 <0,04 2,0
Gammagard 10,7 5,87 2,28 0,56 0,05 <0,07 <0,04 <1
Polygam GIV 25 9,6 6,01 3,34 0,53 0,13 0,09 <0,04 36,6
Polygam GIV 18 8,5 4,93 2,93 0,44 0,15 0,15 <0,04 36,1
Polygam GIV 21 10,2 5,43 2,79 0,53 0,19 0,17 <0,04 43,0
IM Ig preparations
Globuman Berna 9,2 5,39 2,79 0,51 0,19 0,08 0,08 26,0
Beriglobin 10,3 6,01 3,21 0,53 0,25 0,12 0,07 61,4
Intragam GH 74 9,1 4,93 3,49 0,39 0,28 0,16 <0,04 42,7
Intragam GH 66 8,8 4,93 3,06 0,58 0,25 0,15 <0,04 57,1
Intragam GL 99 9,9 6,86 3,34 0,61 0,31 0,24 0,05 60,8
The various IV and IM Ig preparations were tested at a final concentration of 1 9 protein/1oo ml. Levels of IgG, IgA, IgM and IgG subclasses are expressed in gI1, while those of IgE
are expressed as IU/ml.

















IgG, IgG2 IgG3 IgG.
58 31 7 4
59 35 4 2
53 42 4 1
67 26 6 1
60 33 5 1
58 35 5 2
61 31 6 2
61 31 6 2
60 32 5 3
54 38 4 3
56 35 7 3
62 30 5 3
preparations (IV and IM) possessed comparable opsonic
activity for S. aureus, with Gammagard being slightly better
than the others. The various IM preparations possessed
comparable opsonic activity for S. pyogenes, although some
differences were evident with the IV preparations. Octagam
and Gammagard were the most impressive of the IV
preparations in respect of opsonisation of S. pyogenes,
while Sandoglobulin arid Polygam possessed similar
activity. The data for opsonisation of S. pyogenes by pooled
normal serum are shown in the legend to Fig. 2. The
relatively unimpressive activity of pooled normal serum is an
artefact caused by the oxidant-scavenging activity of low-
molecular-weight anti-oxidants such as vitamin C and uric


















Fig. 2. MPO-mediated iodination of S. pyogenes (counts per minute
x 10') by human neutrophils in the presence of the various test IV
and IM Ig preparations. The value for inactivated serum was
17 ± 4 cpm x 10'. In the corresponding Ig-free control systems the
iodination of S. pyog~es was 617 ± 135 cpm. Data are expressed

















Fig. 1. Uptake of radiolabelled S. aureus by human neutrophils
(counts per minute x 10') in the presence of 10% heat-inactivated
pooled normal serum or the various test IV and IM Ig
preparations. Data are expressed as mean ±SE of 3 different
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Discussion
In this study we compared the Ig concentrations and
opsonic activities of the currently available (with the
exception of Octagam) imported and locally manufactured
IM and IV Ig preparations. Of the three IM preparations
tested, the locally manufactured product lntragam compared
extremely favourably with the two imported products
(Beriglobin and Globuman Berna). All three of these IM
products contained high levels of IgG, with the various IgG
subclasses being present in proportions which correspond
to those of normal serum globulin. There was minor, but
similar, contamination by IgA, IgM and IgE. The three IM
preparations possessed similar levels of opsonic activity for
the microbial pathogens S. aureus and S. pyogenes. In a
previous study22 communicated in 1983, we reported that
the locally manufactured IM Ig product performed less
impressively in these assays than Beriglobin. However, the
data presented here demonstrate that Intragam is the equal
of Beriglobin and Globuman Berna in respect of Ig content
and opsonic activity.
Equivalent concentrations of IgG were also present in the
various IV preparations, with the IgG subclasses again
present in representative proportions. When tested at
identical concentrations (1 g/100 ml), all the test IV
preparations were found to possess ?imilar opsonic activity
for S. aureus, while that of Sandoglobulin and Polygam was
less than Gammagard and Octagam for S. pyogenes.
However, the iodination assay used for measuring
opsonisation of S. pyogenes is prone to false-negative
results if oxidant-scavenging activity is present in the assay
system. Additional studies (data not shown) were performed
to investigate the oxidant-scavenging potential of the
various IV 19 preparations, using a cell-free oxidant-
generating system. We observed that Polygam, and to a
lesser extent Sandoglobulin and Octagam, possessed
oxidant-scavenging activity which could not be attributed to
the stabilising agent (sucrose; final concentration of 0,2% in
the assay system). If corrected for in the opsonisation assay
using S. pyogenes (results not shown), the opsonic activities
of the different IV preparations (including Polygam) for this
microbial pathogen were comparable. The locally
manufactured IV product therefore compared favourably
with the imported preparation in respect of levels of total
IgG and IgG subclasses and opsonic activity for microbial
pathogens commonly encountered in individuals with
antibody deficiency states.
The replacement therapy of antibody deficiency
syndromes is a relatively limited clinical application of IV Ig
preparations, and it seems likely that these products will
become increasingly used in the immunotherapy of acute
and chronic inflammatory diseases with both auto-immune
and non-auto-immune causes.'-a23 The mechanisms of
immunosuppressive/anti-inflammatory activity of IV Ig
preparations have not been conclusively established, but
may include interference with the binding of immune
complexes," modulation of the production of pro-
inflammatory cytokines,25 suppression of immune responses
by anti-idiotypic antibodies'· or neutralisation of microbial
superantigens which have been implicated in both the
pathogenesis of auto-immune diseases27 and the activation-
__ Volume84 o. II November 1994 SAMJ
induced destruction of CD4+ T Iymphocytes in HIV-infected
individuals.'·
In conclusion, the locally manufactured IM and IV Ig
preparations Intragam and Polygam compare impressively
with the corresponding imported products, and are likely to
command increasing recognition.
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